REPORT FROM THE AMERICAN ACADEMY OF NEUROLOGY (AAN) 63RD ANNUAL MEETING, HONOLULU, HAWAII, APRIL 9-16, 2011 – Canadian researchers have conducted a meta-analysis of 11 trials (n=253) of N-methyl-D-aspartate (NMDA) antagonists for peak-dose levodopa-induced dyskinesias in Parkinson’s disease (AAN 2011; abstract P05.098). NMDA receptors are involved in dopamine-glutamate interactions.